Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.


Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

What's your initial management strategy for interstitial cystitis/bladder pain syndrome (IC/BPS)?

What's your initial management strategy for interstitial cystitis/bladder ...

Studies have suggested a strong "placebo effect" in the treatment of interstitial cystitis/bladder pain syndrome.

Have you ever had a dialysis patient with calciphylaxis?

Have you ever had a dialysis patient with ...

Calciphylaxis has been increasing significantly in incidence in hemodialysis.

Do you think the U.S. is prepared to contain an Ebola outbreak?

Do you think the U.S. is prepared to ...

Public health officials say the latest Ebola outbreak is the worst to date.